Head-To-Head Survey: Cerecor (CERC) & Its Rivals
Cerecor (NASDAQ: CERC) is one of 527 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Cerecor to similar businesses based on the strength of its profitability, risk, institutional ownership, dividends, analyst recommendations, valuation and earnings.
This table compares Cerecor and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This table compares Cerecor and its competitors revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cerecor||$27.81 million||$11.86 million||8.50|
|Cerecor Competitors||$2.03 billion||$140.19 million||-1.64|
Cerecor’s competitors have higher revenue and earnings than Cerecor. Cerecor is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Cerecor has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Comparatively, Cerecor’s competitors have a beta of 1.17, indicating that their average share price is 17% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Cerecor and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Pharmaceutical preparations” companies have a potential upside of 69.24%. Given Cerecor’s competitors higher probable upside, analysts plainly believe Cerecor has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
41.7% of Cerecor shares are held by institutional investors. Comparatively, 46.4% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 80.2% of Cerecor shares are held by insiders. Comparatively, 15.2% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation. It also offers Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension; and Flexichamber. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and two preclinical stage development candidates, CERC-406 and CERC-425 potential for the treatment of motoric and non-motoric symptoms of Parkinson's disease, as well as other psychiatric and neurological conditions. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.